Get notified when PHGE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — NYSE delisting notice for equity deficiency; must regain compliance by September 2027 or face delisting.
- Departure Of Ceo (new) — Entire management team and board replaced in Q1 2026 as part of strategic pivot from biotech to defense.
- Departure Of Cfo (new) — Entire management team and board replaced in Q1 2026 as part of strategic pivot from biotech to defense.
BiomX abandons biotech, pivots to Israeli defense tech amid NYSE delisting risk
Filed May 5, 2026 · Period ending May 5, 2026 · ~1 min read
Key Changes
-
high
Company exited phage therapy entirely: discontinued lead drug BX004, Israeli subsidiary BiomX Ltd. filed insolvency and is now under court-appointed trustee. Parent company lost control of former core operating asset.
Item 8.01 verify on EDGAR → -
high
Now operates three Israeli defense subsidiaries: DFSL (60% owned, laser radar systems), Zorronet (AI surveillance software with Elbit/Rafael contracts), and X Security (first-response tech including aerial firefighting). Committed $3M+ to fund operations.
Item 8.01 verify on EDGAR → -
high
Received NYSE delisting notice for equity deficiency in March 2026. Must regain compliance by September 2027 or face delisting, which would severely impair liquidity and could trigger convertible note defaults.
Item 8.01 verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FNGR 10-Q) is open in full — no account needed.
Partner
Trade PHGE commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify